Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

642 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolution of MS lesions to black holes under DNA vaccine treatment.
Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW. Papadopoulou A, et al. Among authors: steinman l. J Neurol. 2012 Jul;259(7):1375-82. doi: 10.1007/s00415-011-6361-x. Epub 2012 Jan 6. J Neurol. 2012. PMID: 22222856 Clinical Trial.
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group. Garren H, et al. Among authors: steinman l. Ann Neurol. 2008 May;63(5):611-20. doi: 10.1002/ana.21370. Ann Neurol. 2008. PMID: 18481290 Clinical Trial.
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA; Ozanimod Study Investigators. Harris S, et al. Among authors: steinman l. Eur J Neurol. 2021 Nov;28(11):3722-3730. doi: 10.1111/ene.15009. Epub 2021 Aug 23. Eur J Neurol. 2021. PMID: 34292643 Free PMC article. Clinical Trial.
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Bar-Or A, et al. Among authors: steinman l. Arch Neurol. 2007 Oct;64(10):1407-15. doi: 10.1001/archneur.64.10.nct70002. Epub 2007 Aug 13. Arch Neurol. 2007. PMID: 17698695 Clinical Trial.
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Kappos L, et al. Among authors: steinman l. Nat Med. 2000 Oct;6(10):1176-82. doi: 10.1038/80525. Nat Med. 2000. PMID: 11017151 Clinical Trial.
DNA vaccination in the treatment of autoimmune disease.
Garren H, Steinman L. Garren H, et al. Among authors: steinman l. Curr Dir Autoimmun. 2000;2:203-16. doi: 10.1159/000060505. Curr Dir Autoimmun. 2000. PMID: 11791457 Review. No abstract available.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: steinman l. JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192. JAMA Neurol. 2013. PMID: 23732754 Free PMC article. Clinical Trial.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
642 results